Sitavig

Chickenpox, Encephalitis, Herpes Simplex, Neutropenia + 18 more

Treatment

20 Active Studies for Sitavig

What is Sitavig

Acyclovir

The Generic name of this drug

Treatment Summary

Acyclovir is an antiviral drug used to treat different types of herpes, including herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. It is often the first treatment prescribed for these viruses and can be given to children as young as 6 years old. Acyclovir was approved by the FDA in 1982.

Zovirax

is the brand name

image of different drug pills on a surface

Sitavig Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zovirax

Acyclovir

1982

496

Effectiveness

How Sitavig Affects Patients

Acyclovir is a drug that stops the spread of viruses associated with herpes, such as cold sores. It works by blocking the DNA replication of the virus. Acyclovir is usually safe to take, even in large doses, and so it has a wide range of doses it can be taken at.

How Sitavig works in the body

Acyclovir works by interfering with the virus's ability to reproduce. When a virus infects a cell, it uses an enzyme called thymidine kinase to turn acyclovir into a form called acyclovir monophosphate. This form is then converted to a diphosphate form by guanylate kinase. The diphosphate form is then converted to the active form, acyclovir triphosphate, by enzymes like pyruvate kinase. Acyclovir triphosphate has a high affinity for the virus's DNA polymerase, and

When to interrupt dosage

The prescribed dosage of Sitavig is contingent upon the diagnosed condition, including Cytomegalovirus Infections, grave Genital herpes and Herpes simplex type I resurgence. The measure of dosage is contingent on the technique of delivery (e.g. Cream - Topical or Injection, powder, lyophilized, for solution - Intravenous) as detailed in the table below.

Condition

Dosage

Administration

Bone Marrow Transplant

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Neutropenia

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Simplex Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Chickenpox

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Communicable Diseases

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Immunocompromised

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Genitalis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Shingles

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Keratitis, Herpetic

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Cytomegalovirus Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

prophylaxis of VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Bell Palsy

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Encephalitis, Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

prophylaxis of HSV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Solution, Ointment - Ophthalmic, Cutaneous, Ointment - Cutaneous

Warnings

Sitavig has one contraindication, thus it should not be blended with the ailments enumerated in the following table.

Sitavig Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Acyclovir may interact with Pulse Frequency

There are 20 known major drug interactions with Sitavig.

Common Sitavig Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Acyclovir.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Neomycin.

Procainamide

Major

The excretion of Procainamide can be decreased when combined with Acyclovir.

Tenofovir

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir alafenamide.

Sitavig Toxicity & Overdose Risk

Overdosing on Cyclosporin can cause agitation, loss of consciousness, seizures, and excessive sleepiness. These effects are more likely to occur in those who have not been monitored for fluid levels or kidney function. Treatment for Cyclosporin overdose should involve supportive care and addressing the symptoms.

image of a doctor in a lab doing drug, clinical research

Sitavig Novel Uses: Which Conditions Have a Clinical Trial Featuring Sitavig?

34 clinical studies are presently assessing the potential of Sitavig to prophylactically inhibit Varicella Zoster Virus (VZV) reactivation and reduce the incidence of Immunocompromised and Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Encephalitis, Herpes Simplex

0 Actively Recruiting

Herpes Simplex Infections

0 Actively Recruiting

Herpes Genitalis

0 Actively Recruiting

VZV re-activation

0 Actively Recruiting

Chickenpox

5 Actively Recruiting

Phase 4, Phase 3

Neutropenia

3 Actively Recruiting

Phase 2, Phase 3

Cytomegalovirus Infections

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Bone Marrow Transplant

31 Actively Recruiting

Not Applicable, Early Phase 1, Phase 1, Phase 2

Immunocompromised

3 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Keratitis, Herpetic

0 Actively Recruiting

prophylaxis of HSV re-activation

0 Actively Recruiting

Shingles

2 Actively Recruiting

Phase 2, Phase 1

Herpes Simplex

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

prophylaxis of VZV re-activation

0 Actively Recruiting

Bell Palsy

2 Actively Recruiting

Not Applicable, Early Phase 1

Herpes Labialis

0 Actively Recruiting

Sitavig Reviews: What are patients saying about Sitavig?

4.7

Patient Review

7/21/2020

Sitavig for Cold Sore

This drug is on the pricey side, but it cleared my cold sore quickly and I haven't had one in over 18 months.

1.7

Patient Review

2/10/2015

Sitavig for Cold Sore

Valtrex was more effective for me when taken at the first sign of a cold sore.

1

Patient Review

6/7/2016

Sitavig for Cold Sore

This pill is way too expensive for how ineffective it is. I had to keep taking oral pills even after starting this treatment, and I tried it twice just to give it a chance. No dice.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sitavig

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much does Sitavig cost?

"The average retail price of Sitavig is $1,202.11, 23% off the average retail price of $1,202.11. Compare herpes virus nucleosides."

Answered by AI

How long does it take for Sitavig to dissolve?

"When the tablet is applied to the gums, it needs to stay there for 6 hours, but it may take up to 14 hours to dissolve."

Answered by AI

What is Sitavig used for?

"SITAVIG is a prescription medicine that is used to treat cold sores in adults who have normal immune systems."

Answered by AI

Is Sitavig covered by insurance?

"Your doctor can prescribe a drug called Sitavig. The cost of the drug depends on your insurance coverage, any prescription deductibles you have, and your prescription copay. There is a patient access card for Sitavig which may reduce the copay for qualifying patients."

Answered by AI

Clinical Trials for Sitavig

Image of University of Kansas Medical Center- Sleep, Health and Wellness Laboratory in Kansas City, United States.

Cognitive Behavioral Therapy for Insomnia Before Bone Marrow Transplant

18+
All Sexes
Kansas City, KS

This proposed study is a prospective, randomized, controlled Phase 1 clinical trial to determine feasibility, acceptability (Aim 1) and preliminary effect (Aim 2) to mitigate insomnia symptoms and fatigue and improve health-related quality of life in patients who are planning to undergo HSCT. The investigators plan to enroll n=30 with insomnia symptoms (Insomnia Severity Index ≥10) who will be randomized into one of two groups: 1. A group that starts CBT-I after the initial evaluation visit with the HSCT care team (Early CBT-I), or 2. Treatment as usual (TAU). Participants in the CBT-I group will receive six sessions of telehealth-delivered CBT-I that is completed prior to transplant. Reassessments will occur post-intervention (\~1-2 weeks before HSCT) and 1- and 3-months post-HSCT.

Phase 1
Recruiting

University of Kansas Medical Center- Sleep, Health and Wellness Laboratory

Image of Children's Clinic of Jonesboro, AR in Jonesboro, United States.

MMRV Vaccines for Measles, Mumps, Rubella, and Chickenpox

4 - 6
All Sexes
Jonesboro, AR

The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response. It will also compare the overall immune response to the MMRVNS vaccine with that of the Merck licensed measles, mumps, rubella, and varicella (MMRV) vaccine. The vaccines will be given as a second dose to children aged 4 to 6 years who have previously received a first dose of any combination of measles, mumps, rubella, and varicella-containing vaccine(s). The study will also assess the immune response and safety of the MMRVNS and MMRV vaccines when given at the same time as a diphtheria, tetanus, acellular pertussis, and inactivated poliovirus (DTaP-IPV) vaccine. The DTaP-IPV vaccine used is licensed as Kinrix in the United States.

Phase 3
Waitlist Available

Children's Clinic of Jonesboro, AR (+35 Sites)

GlaxoSmithKline

Have you considered Sitavig clinical trials?

We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.
Go to Trials
Image of University Hospital in San Antonio, United States.

Letermovir for Cytomegalovirus in Kidney Transplants

18+
All Sexes
San Antonio, TX

The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive. To do this, researchers will compare patients who received letermovir with a group of historical patients who received valganciclovir ("mini dose"). Both groups will be on CMV prophylaxis drug for 90 days post-transplant. The main question the study wants to answer is: • Does letermovir work as well as valganciclovir in preventing CMV infections during the first 12 months after a kidney transplant? The study will also look at other important questions: * Is letermovir easier for patients to tolerate than valganciclovir? * How long does it take for a CMV infection to appear in each group? * Are there differences in "breakthrough" CMV infections between the two medications? * For patients who develop CMV that becomes resistant to treatment, are the resistance patterns different between the two groups

Phase 4
Waitlist Available

University Hospital

Image of Stein Eye Institute, University of California Los Angeles in Los Angeles, United States.

Valganciclovir + Ganciclovir for Cytomegalovirus Anterior Uveitis

18+
All Sexes
Los Angeles, CA

The goal of this clinical trial is to compare antiviral treatment strategies for cytomegalovirus (CMV) anterior uveitis - a viral infection causing inflammation inside the front of the eye - in immunocompetent adults aged 18 years and older. The main questions it aims to answer are: Does oral valganciclovir reduce aqueous humor CMV viral load more effectively than topical ganciclovir 2% eye drops or placebo after 7 days of treatment (Trial I)? Does long-term suppressive antiviral therapy (oral valganciclovir or topical ganciclovir 2% eye drops) reduce the rate of CMV anterior uveitis recurrence over 12 months compared to placebo (Trial II)? Researchers will compare oral valganciclovir, topical ganciclovir 2% eye drops, and placebo to see if either antiviral treatment reduces viral load and controls eye inflammation more effectively in the short term, and whether long-term antiviral suppression can prevent the disease from coming back after the inflammation has been controlled. Participants will: * Undergo anterior chamber paracentesis (removal of a small amount of fluid from the front of the eye) for PCR testing to confirm CMV as the cause of their eye inflammation before enrollment * Be randomly assigned to receive oral valganciclovir 900 mg twice daily, topical ganciclovir 2% eye drops six times daily, or placebo for 7 days (Trial I), in addition to standard steroid eye drops * Return for follow-up visits at Day 7 and Day 21 for eye examinations, laboratory blood tests, and a second anterior chamber paracentesis at Day 7 to measure viral load after treatment * If eye inflammation is controlled after Trial I, be offered enrollment into Trial II, where they will be randomly assigned to long-term suppressive oral valganciclovir, topical ganciclovir 2% eye drops, or placebo for 12 months, with follow-up visits approximately every 2 months and additional visits if inflammation returns

Phase 2
Waitlist Available

Stein Eye Institute, University of California Los Angeles (+1 Sites)

John A Gonzales, MD

Have you considered Sitavig clinical trials?

We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.
Go to Trials
Image of Georgetown University School of Medicine in Washington, United States.

Mosaic Website for Blood Cancer Patients

18+
All Sexes
Washington, United States

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.

Recruiting
Has No Placebo

Georgetown University School of Medicine (+3 Sites)

Image of University of Kansas Cancer Center in Kansas City, United States.

High Intensity Interval Training for Bone Marrow Transplant

18 - 80
All Sexes
Kansas City, KS

The goal of this clinical trial is to learn how a remotely monitored high-intensity interval training (REMM-HIIT) affects the cardiorespiratory fitness and physical function for patients planning to undergo stem cell transplantation. The main questions it aims to answer are: Is there a change in the participant's cardiorespiratory fitness level? Is there a change in the participant's physical function? Researchers will compare the REMM-HIIT program to a control group of participants who do not take part in the training program to see if REMM-HIIT helps improve stem cell transplantation outcomes. Participants will: * Complete cardiopulmonary exercise testing (CPET) 4 times during the study * Do basic tests to measure physical function 6 times during the study * Answer questions about their life and how they are feeling 6 times during the study * Wear a device to keep track of step counts and heart rate daily * Keep a log of every time they exercise throughout the study * Optionally, provide blood and stool samples 6 times during the study

Waitlist Available
Has No Placebo

University of Kansas Cancer Center (+2 Sites)

Anthony Sung, MD

Image of Eye Institute of Alberta, Royal Alexandra Hospital in Edmonton, Canada.

Suture Lid Spring for Facial Nerve Palsy

18+
All Sexes
Edmonton, Canada

The eyelids protect the cornea and eyelid closure is essential to ocular health and clear vision. Patients with permanent Bells palsy or facial nerve palsy from other reasons such as tumours or trauma may be unable to blink and protect their cornea. Irreversible visual loss can occur if the cornea is not kept lubricated. Current treatment options for patients whose eyelid blink does not recover include lubricating the eye every hour or two with drops and lubricating ointment at night, patching the eye closed, sewing parts of the eyelid together (tarsorrpahy), upper lid gold weight or a dental wire spring. It is inconvenient to lubricate the cornea constantly, and the lubricating drops and ointment usually cost more than $80.00 per month. Lubrication often blurs vision, because the patient must look through a film. Patching the eye closed and tarsorraphy deprives the patient of peripheral vision, can impede social interaction, and is objectionable cosmetically. Upper-lid gold weights can be placed underneath the eyelid skin and work by gravity. A gold weight will only work when the patient initiates a forced blink. Gold weights may not work when the patient is lying down because there is no gravity to assist lid closure. The eyelid skin is the thinnest skin in the body and can extrude through the skin over time. Eyelid springs made of metal dental wire exist but are not frequently used because they often extrude through the thin eyelid skin. Also, dental wire springs require attachment to the bone near the side of the eye. It is not uncommon that dental wire springs have to be removed or replaced. The investigators propose a new spring to close the eyelid made out of the surgical stitches (sutures) commonly used in medicine and eyelid surgery. The stitch will be made into a custom shape and attached underneath the skin near the centre of the lid, without attachment to the bone. Upper lid gold weights, dental wire springs, and our proposed suture spring are all foreign bodies and can all become infected or extrude through the skin. Because the suture spring is thinner than a gold weight and because it does not have sharp edges like a metal spring, there should be less risk of extrusion. The suture spring will lose its elasticity over time and will require replacement.

Phase < 1
Recruiting

Eye Institute of Alberta, Royal Alexandra Hospital

Edsel Ing, MD PhD FRCSC

Have you considered Sitavig clinical trials?

We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.
Go to Trials